Bristol's Yervoy Gets A Bigger Advisory Committee Cushion
This article was originally published in The Pink Sheet Daily
The melanoma drug goes up for review by the Oncologic Drugs Advisory Committee Feb. 9, more than six weeks before the PDUFA date of March 26.
You may also be interested in...
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.